Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

By sjmartinez • May 19, 2025

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385. Epub ahead of print. PMID: 40384092.

Tags: Anti-CTLA-4, anti-PD-L1, Cedars Sinai DoM, Hematology/Oncology, immune checkpoint inhibitors, Publications, safety, survival

Estimating the Proportion of Adverse Pregnancy Outcomes Prevented With Improved Early Pregnancy Cardiovascular Health

Borrowman JD, Huang X, Perak AM, Chung JH, Catov JM, Thelilen LH, Bairey Merz CN, Levine LD, Greenland P, Yee LM, Grobman WA, Khan SS,[...]

Comprehensive Assessment of Direct and Passive Smoking Across the Pancreatitis Spectrum

Han S, Yadav D, Xu J, Bellin MD, Fisher WE, Fogel EL, Forsmark C, Hart PA, Li L, Pandol SJ, Park WG, Trikudanathan G, Van[...]

Computational frameworks for enhanced extracellular vesicle biomarker discovery

Kim J, Yang JD, Agopian VG, Zhu Y, Tseng HR, You S. Computational frameworks for enhanced extracellular vesicle biomarker discovery. Exp Mol Med. 2026 Jan[...]